Skip to content

Atezolizumab

Tecentriq (atezolizumab) is an antibody pharmaceutical. Atezolizumab was first approved as Tecentriq on 2016-05-18. It is used to treat non-small-cell lung carcinoma and urinary bladder neoplasms in the USA. It has been approved in Europe to treat breast neoplasms, non-small-cell lung carcinoma, small cell lung carcinoma, transitional cell carcinoma, and urologic neoplasms. The pharmaceutical is active against programmed cell death 1 ligand 1.
Trade Name Tecentriq
Common Name Atezolizumab
Indication breast neoplasms, non-small-cell lung carcinoma, small cell lung carcinoma, transitional cell carcinoma, urinary bladder neoplasms, urologic neoplasms
Drug Class Monoclonal antibodies: humanized, immunomodulating
Atezolizumab
Get full access now